keyboard_arrow_up

North American Injectable Drug Delivery Market worth $16.6 billion by 2017

The report "North America Injectable Drug Delivery Market– by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017" analyzes and studies the major market drivers, restraints, and opportunities in United States and Canada.

Browse 130 market data tables with 28 figures spread through 280 pages and in-depth TOC on "North America Injectable Drug Delivery Market"
http://www.marketsandmarkets.com/Market-Reports/north-america-injectable-drug-delivery-market-1109.html
Early buyers will receive 10% customization on this report.

This report studies the North American injectable drug delivery technologies market over the forecast period of 2012-2017.

The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012 and is poised to grow at a CAGR of 12.3% from 2012 to 2017 to reach $16.6 billion by 2017.

The injectable drug delivery technologies market is broadly categorized into two major segments, namely, devices technologies and formulation technologies. Based on product, the injectable drug delivery devices technologies market is further categorized into conventional injection devices, self-injection devices, and others (microneedles, nanoneedles and blunt needle injections), while injectable drug delivery formulation technologies market is categorized into conventional drug delivery formulations and novel drug delivery formulations. Conventional injection devices segment accounted for the largest share of the overall injectable drug delivery technologies market in 2012.

Talk to Our Research Analysts for More Info@
http://www.marketsandmarkets.com/speaktoanalyst.asp?id=1109

In addition, the market is segmented on the basis of its therapeutic applications such as auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, and Wilsons disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment). Hormonal disorders commanded the largest share of the global injectable drug delivery technologies market in 2012. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self-injection devices.


The major markets covered in this report are United States and Canada. The United States accounted for the largest market of the North American injectable drug delivery technologies market in the year 2012. The growth of the injectable drug delivery technologies market is primarily triggered by innovations in injectable drug delivery devices, surge of biologics, rising prevalence of diabetes in the U.S. and Canada, improvement in patient compliance and incessant rise in partnerships, collaborations and acquisitions among prominent players in this market. However, factors such as product recalls, stringent regulatory systems and needle-stick injuries and infections are restraining the growth of the market.

Get The Sample Copy Of This Report:
http://www.marketsandmarkets.com/requestsample.asp?id=1109

The report includes company profiles of major players such as Eli Lilly & Co. (U.S.), Sanofi (France), Novo Nordisk A/S (Denmark), Baxter International, Inc. (U.S.), Becton Dickinson & Co. (U.S.), and Hospira Inc. (U.S.). Other prominent players in North America are West Pharmaceutical Services, Inc. (U.S.), Unilife Corporation (U.S.), Antares Pharma, Inc. (U.S.), and Zogenix, Inc. (U.S.), among others.

About MarketsandMarkets:
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Subscribe Reports from Healthcare Domain @ http://www.marketsandmarkets.com/Subscription.html

Contact:
Mr. Rohan

Unit No. 802, 8th Floor,
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune – 411013,
Maharashtra, India.
Tel: +1-888-6006-441.
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets